Form 10-Q Acumen Pharmaceuticals, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BTIG Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)
August 14, 2024 6:12 AM EDTBTIG analyst Thomas Schrader reiterated a Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).
The analyst comments "Enrolling a trial with a placebo arm when an active commercial drug is available is historically challenging, so we see Acumen's comments about the rapid enrollment of the P2 trial for Sabirnetug as very encouraging. Talking with management, both the therapeutic premise of a safer antibody that may also be more... More
